News Channels

08 Dec 2017 Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy (NPDR) Discontinued due to Slow Recruitment Rate
08 Dec 2017 Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine
07 Dec 2017 Dicerna Announces First Human Dosed in Phase 1 Clinical Trial of DCR-PHXC for Treatment of All Forms of Primary Hyperoxaluria
07 Dec 2017 BlackThorn Therapeutics Presents Preclinical and Clinical Data From Its First-in-Class NOPR Antagonist at American College of Neuropsychopharmacology Annual Meeting
07 Dec 2017 Seattle Genetics Presents Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A) in Patients with Triple Negative Breast Cancer at 2017 San Antonio Breast Cancer Symposium
07 Dec 2017 Aerogen Pharma and Lyomark Pharma Partner to Develop Inhaled Surfactant, Begin a Phase 2 Clinical Trial
07 Dec 2017 Glenmark Pharmaceuticals Announces Dosing of First Patient With Investigational Immuno-Oncology Agent GBR 1342
07 Dec 2017 Aptinyx Granted Fast Track Designation, Initiates Phase 1 for Second Clinical Candidate, NYX-783, in Post-Traumatic Stress Disorder
07 Dec 2017 CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy, CTX001 in β-thalassemia
07 Dec 2017 Sage Therapeutics Reports Positive Top-line Results from Phase 2 Placebo-Controlled Trial of SAGE-217 in Major Depressive Disorder
07 Dec 2017 bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy
07 Dec 2017 Vertex Announces Positive Results from Open-Label Phase 3 Study of KALYDECO(R) (ivacaftor) in Children with Cystic Fibrosis Ages 1 to 2 Years
07 Dec 2017 Pieris Pharmaceuticals Announces Ethics and Regulatory Clearance to Begin Clinical Testing of Inhaled Respiratory Program, PRS-060/AZD1402
07 Dec 2017 Alexion and Halozyme Enter License Agreement for ENHANZE Technology
07 Dec 2017 Zealand Pharma initiates the pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
07 Dec 2017 Sanofi explores combination treatments for multiple myeloma in new late-stage trials
07 Dec 2017 XOMA Announces Exclusive License Agreement for XOMA 358 with Rezolute, Inc.
07 Dec 2017 H3 Biomedicine Presents Preclinical Data on Novel ERα Antagonist at San Antonio Breast Cancer Symposium
07 Dec 2017 Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
07 Dec 2017 Vedanta Biosciences Announces Initiation of Phase 1a/1b Trial for New Drug Class of Rationally-Defined Bacterial Consortia Derived from the Human Microbiome

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing